ImmuneOncia Therapeutics Inc.

As of June 30, 2026, ImmuneOncia Therapeutics Inc. carries a market capitalization of 326.47B, placing it among publicly traded companies globally. Its enterprise value stands at 233.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ImmuneOncia Therapeutics Inc. has 91.19M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, ImmuneOncia Therapeutics Inc. maintains a current ratio of 22.02, meaning it holds 22.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.04, indicating conservative leverage, while an interest coverage ratio of -6,900.36 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ImmuneOncia Therapeutics Inc. posted a negative return on equity (ROE) of -39.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.32, reflecting losses generated across the asset base.

As of the close on October 23, 2026, ImmuneOncia Therapeutics Inc.'s stock has declined approximately 46.90% over the past 52 weeks. The 50-day moving average sits at 3,125.40, while the 200-day moving average is 5,817.16.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -29.45B, while operating income came in at -30.19B.

As of June 30, 2026, ImmuneOncia Therapeutics Inc. holds 93.17B in cash and equivalents against 41.65M in total debt, resulting in a net debt position of -83.07B. Total book value stands at 100.28B, with working capital of 94.61B providing operational flexibility.

ImmuneOncia Therapeutics Inc. produced -26.30B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -531.20M in capital expenditures, free cash flow totaled -26.83B - equivalent to -334.69 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -25.06, meaning ImmuneOncia Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

ImmuneOncia Therapeutics Inc.'s most recent stock split took place on April 3, 2026 with a 248:267 split ratio.